Brainomix Joins the Elite Future Fifty Scale-Up Programme in the UK

Brainomix Selected for Future Fifty Scale-Up Programme

Brainomix, a prominent player in the field of AI-powered medical imaging, recently announced its selection for the renowned Future Fifty programme, which recognizes the most promising high-growth technology companies in the UK. This selection underscores Brainomix's continuous advancement in innovation and global reach, particularly in the critical areas of stroke and lung disease diagnostics.

About the Future Fifty Programme

The Future Fifty initiative, organized by Tech Nation and Founders Forum Group, is an exclusive programme aimed at supporting the UK’s leading scale-up businesses. Companies included in this programme have demonstrated significant potential for growth, and noteworthy achievements in their respective sectors. Notably, this programme has been pivotal in the success of 30% of all UK tech unicorns, along with 40% of the country’s decacorns.

Joining the latest cohort of Future Fifty are 24 other remarkable UK-based companies that span a diverse array of sectors such as healthtech, biotech, fintech, AI, energy, and advanced manufacturing. Collectively, these companies have secured approximately £1.47 billion in funding and employ over 3,800 individuals across various industries.

Brainomix's Innovative Contributions

Brainomix, headquartered in Oxford, specializes in transforming medical imaging through artificial intelligence. The company’s acclaimed Brainomix 360 Stroke platform empowers clinicians with precise insights for stroke assessment, enhancing their ability to make informed treatment choices. Additionally, the company’s e-Lung imaging solution utilizes advanced algorithms to analyze CT scans, promoting better management of lung diseases. With operations in over 20 countries, Brainomix is establishing itself as a global standard in the medical imaging field.

Dr. Michalis Papadakis, CEO and co-founder of Brainomix, expressed his pride in joining the Future Fifty community, highlighting the recognition as validation of the company’s efforts and the positive impact it aims to deliver in the healthcare industry. He mentioned, “As we continue to scale internationally, Future Fifty provides an exceptional network and community from which we can learn, build new relationships, and accelerate our ambitions.”

Growth and Achievements

The selection to Future Fifty comes at a time when Brainomix is experiencing remarkable growth. The company has successfully raised £49 million through various funding channels, attained over 30 regulatory clearances from major health authorities like the FDA and CE, and significantly expanded its market presence internationally. This momentum highlights the increasing adoption of its AI-driven imaging solutions.

The Future Fifty programme not only acts as a formidable platform for companies like Brainomix to showcase their innovations but also facilitates connections with influential leaders in the tech industry. As Brainomix embarks on this exciting new chapter, it aims to enhance its products further and solidify its footprint in key global markets, working towards a more data-driven, patient-centric approach in healthcare.

For anyone interested in learning more about Brainomix and its groundbreaking technology, further information can be found on their official website at www.brainomix.com.